Epstein–Barr virus infections: prospects for treatment
Epstein–Barr virus (EBV) causes infectious mononucleosis and oral hairy leucoplakia, and is associated with a number of malignancies. There are, however, no regulatory agency-approved treatments for EBV-related diseases. Several antiviral drugs inhibit replication of EBV in cell culture including ac...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2005-08, Vol.56 (2), p.277-281 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 281 |
|---|---|
| container_issue | 2 |
| container_start_page | 277 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 56 |
| creator | Gershburg, Edward Pagano, Joseph S. |
| description | Epstein–Barr virus (EBV) causes infectious mononucleosis and oral hairy leucoplakia, and is associated with a number of malignancies. There are, however, no regulatory agency-approved treatments for EBV-related diseases. Several antiviral drugs inhibit replication of EBV in cell culture including acyclic nucleoside and nucleotide analogues and pyrophosphate analogues, all of which inhibit the EBV DNA polymerase. Despite their potency in vitro, these drugs have limited use in vivo for treatment of acute primary EBV infection as well as EBV-associated malignancies for several reasons. Here we discuss novel anti-EBV compounds, including maribavir, potentially useful for the treatment of acute EBV infections. A number of experimental approaches for treatment of EBV-related malignancies that are not susceptible to conventional antiviral drug treatment are also discussed. |
| doi_str_mv | 10.1093/jac/dki240 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68431475</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17639806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-d030e2668d4f2165b87642931df7b69feeae9ecb6180f1f9cce844147682d5b33</originalsourceid><addsrcrecordid>eNqF0UFLwzAUB_AgipvTix9AiqAHoS5p0iT1pnM6ZajIBPES0jSBzK2tSSt68zv4Df0kRjZUvHhKwvvxeO8fALYRPEQww_2pVP3i0SYEroAuIhTGCczQKuhCDNOYkRR3wIb3UwghTSlfBx1Ew5UQ3gV8WPtG2_Lj7f1EOhc9W9f6yJZGq8ZWpT-Kalf5Orx8ZCoXNU7LZq7LZhOsGTnzemt59sDd2XAyGMXj6_OLwfE4VoSwJi7CDDqhlBfEJIimOWeUJBlGhWE5zYzWUmda5RRxaJDJlNKcEEQY5UmR5hj3wP6ib5jjqdW-EXPrlZ7NZKmr1gvKCQ48_RciRnHGIQ1w9w-cVq0rwxIiCYilIZ2ADhZIhfW900bUzs6lexUIiq_URUhdLFIPeGfZsc3nuvihy5gD2FsC6ZWcGSdLZf0vl3HMGAsuXjgbPuXluy7do6AMs1SM7h_EBCbw9PLmVlzhT7M-mZc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217675160</pqid></control><display><type>article</type><title>Epstein–Barr virus infections: prospects for treatment</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Gershburg, Edward ; Pagano, Joseph S.</creator><creatorcontrib>Gershburg, Edward ; Pagano, Joseph S.</creatorcontrib><description>Epstein–Barr virus (EBV) causes infectious mononucleosis and oral hairy leucoplakia, and is associated with a number of malignancies. There are, however, no regulatory agency-approved treatments for EBV-related diseases. Several antiviral drugs inhibit replication of EBV in cell culture including acyclic nucleoside and nucleotide analogues and pyrophosphate analogues, all of which inhibit the EBV DNA polymerase. Despite their potency in vitro, these drugs have limited use in vivo for treatment of acute primary EBV infection as well as EBV-associated malignancies for several reasons. Here we discuss novel anti-EBV compounds, including maribavir, potentially useful for the treatment of acute EBV infections. A number of experimental approaches for treatment of EBV-related malignancies that are not susceptible to conventional antiviral drug treatment are also discussed.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dki240</identifier><identifier>PMID: 16006448</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; antiviral drugs ; Biological and medical sciences ; EBV ; Epstein-Barr Virus Infections - drug therapy ; Epstein-Barr Virus Infections - virology ; Herpesvirus 4, Human - drug effects ; Herpesvirus 4, Human - physiology ; Humans ; infectious mononucleosis ; Medical sciences ; Pharmacology. Drug treatments ; Virus Replication - drug effects</subject><ispartof>Journal of antimicrobial chemotherapy, 2005-08, Vol.56 (2), p.277-281</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Aug 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-d030e2668d4f2165b87642931df7b69feeae9ecb6180f1f9cce844147682d5b33</citedby><cites>FETCH-LOGICAL-c447t-d030e2668d4f2165b87642931df7b69feeae9ecb6180f1f9cce844147682d5b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16983777$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16006448$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gershburg, Edward</creatorcontrib><creatorcontrib>Pagano, Joseph S.</creatorcontrib><title>Epstein–Barr virus infections: prospects for treatment</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J. Antimicrob. Chemother</addtitle><description>Epstein–Barr virus (EBV) causes infectious mononucleosis and oral hairy leucoplakia, and is associated with a number of malignancies. There are, however, no regulatory agency-approved treatments for EBV-related diseases. Several antiviral drugs inhibit replication of EBV in cell culture including acyclic nucleoside and nucleotide analogues and pyrophosphate analogues, all of which inhibit the EBV DNA polymerase. Despite their potency in vitro, these drugs have limited use in vivo for treatment of acute primary EBV infection as well as EBV-associated malignancies for several reasons. Here we discuss novel anti-EBV compounds, including maribavir, potentially useful for the treatment of acute EBV infections. A number of experimental approaches for treatment of EBV-related malignancies that are not susceptible to conventional antiviral drug treatment are also discussed.</description><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>antiviral drugs</subject><subject>Biological and medical sciences</subject><subject>EBV</subject><subject>Epstein-Barr Virus Infections - drug therapy</subject><subject>Epstein-Barr Virus Infections - virology</subject><subject>Herpesvirus 4, Human - drug effects</subject><subject>Herpesvirus 4, Human - physiology</subject><subject>Humans</subject><subject>infectious mononucleosis</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Virus Replication - drug effects</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0UFLwzAUB_AgipvTix9AiqAHoS5p0iT1pnM6ZajIBPES0jSBzK2tSSt68zv4Df0kRjZUvHhKwvvxeO8fALYRPEQww_2pVP3i0SYEroAuIhTGCczQKuhCDNOYkRR3wIb3UwghTSlfBx1Ew5UQ3gV8WPtG2_Lj7f1EOhc9W9f6yJZGq8ZWpT-Kalf5Orx8ZCoXNU7LZq7LZhOsGTnzemt59sDd2XAyGMXj6_OLwfE4VoSwJi7CDDqhlBfEJIimOWeUJBlGhWE5zYzWUmda5RRxaJDJlNKcEEQY5UmR5hj3wP6ib5jjqdW-EXPrlZ7NZKmr1gvKCQ48_RciRnHGIQ1w9w-cVq0rwxIiCYilIZ2ADhZIhfW900bUzs6lexUIiq_URUhdLFIPeGfZsc3nuvihy5gD2FsC6ZWcGSdLZf0vl3HMGAsuXjgbPuXluy7do6AMs1SM7h_EBCbw9PLmVlzhT7M-mZc</recordid><startdate>20050801</startdate><enddate>20050801</enddate><creator>Gershburg, Edward</creator><creator>Pagano, Joseph S.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20050801</creationdate><title>Epstein–Barr virus infections: prospects for treatment</title><author>Gershburg, Edward ; Pagano, Joseph S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-d030e2668d4f2165b87642931df7b69feeae9ecb6180f1f9cce844147682d5b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>antiviral drugs</topic><topic>Biological and medical sciences</topic><topic>EBV</topic><topic>Epstein-Barr Virus Infections - drug therapy</topic><topic>Epstein-Barr Virus Infections - virology</topic><topic>Herpesvirus 4, Human - drug effects</topic><topic>Herpesvirus 4, Human - physiology</topic><topic>Humans</topic><topic>infectious mononucleosis</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Virus Replication - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gershburg, Edward</creatorcontrib><creatorcontrib>Pagano, Joseph S.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gershburg, Edward</au><au>Pagano, Joseph S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epstein–Barr virus infections: prospects for treatment</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J. Antimicrob. Chemother</addtitle><date>2005-08-01</date><risdate>2005</risdate><volume>56</volume><issue>2</issue><spage>277</spage><epage>281</epage><pages>277-281</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Epstein–Barr virus (EBV) causes infectious mononucleosis and oral hairy leucoplakia, and is associated with a number of malignancies. There are, however, no regulatory agency-approved treatments for EBV-related diseases. Several antiviral drugs inhibit replication of EBV in cell culture including acyclic nucleoside and nucleotide analogues and pyrophosphate analogues, all of which inhibit the EBV DNA polymerase. Despite their potency in vitro, these drugs have limited use in vivo for treatment of acute primary EBV infection as well as EBV-associated malignancies for several reasons. Here we discuss novel anti-EBV compounds, including maribavir, potentially useful for the treatment of acute EBV infections. A number of experimental approaches for treatment of EBV-related malignancies that are not susceptible to conventional antiviral drug treatment are also discussed.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>16006448</pmid><doi>10.1093/jac/dki240</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2005-08, Vol.56 (2), p.277-281 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68431475 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Free Full-Text Journals in Chemistry |
| subjects | Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral Agents - pharmacology Antiviral Agents - therapeutic use antiviral drugs Biological and medical sciences EBV Epstein-Barr Virus Infections - drug therapy Epstein-Barr Virus Infections - virology Herpesvirus 4, Human - drug effects Herpesvirus 4, Human - physiology Humans infectious mononucleosis Medical sciences Pharmacology. Drug treatments Virus Replication - drug effects |
| title | Epstein–Barr virus infections: prospects for treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T07%3A00%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epstein%E2%80%93Barr%20virus%20infections:%20prospects%20for%20treatment&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Gershburg,%20Edward&rft.date=2005-08-01&rft.volume=56&rft.issue=2&rft.spage=277&rft.epage=281&rft.pages=277-281&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dki240&rft_dat=%3Cproquest_cross%3E17639806%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217675160&rft_id=info:pmid/16006448&rfr_iscdi=true |